Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 1
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Anti CD38 monoclonal antibodies for multiple myeloma treatment.
Gozzetti A, Ciofini S, Simoncelli M, Santoni A, Pacelli P, Raspadori D, Bocchia M. Gozzetti A, et al. Among authors: pacelli p. Hum Vaccin Immunother. 2022 Nov 30;18(5):2052658. doi: 10.1080/21645515.2022.2052658. Epub 2022 Apr 11. Hum Vaccin Immunother. 2022. PMID: 35404740 Free PMC article. Review.
Anti-BCMA novel therapies for multiple myeloma.
Sammartano V, Franceschini M, Fredducci S, Caroni F, Ciofini S, Pacelli P, Bocchia M, Gozzetti A. Sammartano V, et al. Among authors: pacelli p. Cancer Drug Resist. 2023 Mar 22;6(1):169-181. doi: 10.20517/cdr.2022.138. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37065871 Free PMC article. Review.
Drug resistance and minimal residual disease in multiple myeloma.
Gozzetti A, Ciofini S, Sicuranza A, Pacelli P, Raspadori D, Cencini E, Tocci D, Bocchia M. Gozzetti A, et al. Among authors: pacelli p. Cancer Drug Resist. 2022 Feb 16;5(1):171-183. doi: 10.20517/cdr.2021.116. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35582527 Free PMC article. Review.
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR).
Abruzzese E, Bocchia M, Trawinska MM, Raspadori D, Bondanini F, Sicuranza A, Pacelli P, Re F, Cavalleri A, Farina M, Malagola M, Russo D, De Fabritiis P, Bernardi S. Abruzzese E, et al. Among authors: pacelli p. Cancers (Basel). 2023 Aug 15;15(16):4112. doi: 10.3390/cancers15164112. Cancers (Basel). 2023. PMID: 37627140 Free PMC article.
Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26+ leukemia stem cells.
Pacelli P, Santoni A, Sicuranza A, Abruzzese E, Giai V, Crugnola M, Annunziata M, Galimberti S, Iurlo A, Luciano L, Sorà F, Fava C, Bestoso E, Marzano C, Cartocci A, Defina M, Sammartano V, Cencini E, Raspadori D, Bocchia M. Pacelli P, et al. Front Pharmacol. 2023 May 26;14:1194712. doi: 10.3389/fphar.2023.1194712. eCollection 2023. Front Pharmacol. 2023. PMID: 37305536 Free PMC article.
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia.
Raspadori D, Pacelli P, Sicuranza A, Abruzzese E, Iurlo A, Cattaneo D, Gozzini A, Galimberti S, Baratè C, Pregno P, Nicolosi M, Sorà F, Annunziata M, Luciano L, Caocci G, Moretti S, Sgherza N, Fozza C, Russo S, Usala E, Liberati MA, Ciofini S, Trawinska MM, Gozzetti A, Bocchia M. Raspadori D, et al. Among authors: pacelli p. Cytometry B Clin Cytom. 2019 Jul;96(4):294-299. doi: 10.1002/cyto.b.21764. Epub 2019 Feb 3. Cytometry B Clin Cytom. 2019. PMID: 30714299 Free PMC article. Clinical Trial.
11 results